We serve Chemical Name:4-Hydroxy-3-methylcyclohexanone CAS:89897-04-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Hydroxy-3-methylcyclohexanone
CAS.NO:89897-04-1
Synonyms:4-hydroxy-3-methylcyclohexan-1-one;Cyclohexanone, 4-hydroxy-3-methyl-;4-Hydroxy-3-methylcyclohexanone
Molecular Formula:C7H12O2
Molecular Weight:128.169
HS Code:2914400090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:229.7±33.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.480
PSA:37.30000
Exact Mass:128.083725
LogP:-0.04
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-hydroxy-3-methylcyclohexan-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Hydroxy-3-methylcyclohexanone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Hydroxy-3-methylcyclohexanone Use and application,4-hydroxy-3-methylcyclohexan-1-one technical grade,usp/ep/jp grade.
Related News: International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation. 4-Hydroxy-3-methylcyclohexanone manufacturer This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. 4-Hydroxy-3-methylcyclohexanone supplier The new restrictions on foreign nationals begin on February 3, Prime Minister Jacinda Ardern announced in a press release Sunday. 4-Hydroxy-3-methylcyclohexanone vendor This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. 4-Hydroxy-3-methylcyclohexanone factory Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.
